|
|
Volumn 13, Issue 6, 2012, Pages 573-574
|
|
NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIANDROGEN;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;
CABAZITAXEL;
DOCETAXEL;
TAXOID;
AGED;
CANCER INVASION;
CANCER STAGING;
DISEASE FREE SURVIVAL;
DRUG RESISTANCE;
EVIDENCE BASED MEDICINE;
HUMAN;
MALE;
MIDDLE AGED;
MORTALITY;
NOTE;
PATHOLOGY;
PRACTICE GUIDELINE;
PROGNOSIS;
PROSTATE TUMOR;
REMISSION;
SURVIVAL;
TREATMENT OUTCOME;
UNITED KINGDOM;
AGED;
ANDROGEN ANTAGONISTS;
ANTINEOPLASTIC AGENTS, HORMONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
DISEASE-FREE SURVIVAL;
DRUG RESISTANCE, NEOPLASM;
EVIDENCE-BASED MEDICINE;
GREAT BRITAIN;
HUMANS;
MALE;
MIDDLE AGED;
NEOPLASM INVASIVENESS;
NEOPLASM STAGING;
PRACTICE GUIDELINES AS TOPIC;
PROGNOSIS;
PROSTATIC NEOPLASMS;
REMISSION INDUCTION;
SURVIVAL ANALYSIS;
TAXOIDS;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 84864916407
PISSN: None
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/s1470-2045(12)70220-6 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|
